Canarys Launches Auryis: AI-Powered Compliance Platform Revolutionizes Pharma and Life Sciences

Bengaluru, India – August 25, 2024 – Canarys, a leading IT solutions provider with over 30 years of experience, has announced the launch of Auryis, a groundbreaking AI-powered unified compliance assessment platform designed specifically for the pharmaceutical and life sciences industries. This launch marks a significant shift for Canarys, transitioning from a primarily services-based organization to a product-led company focused on delivering innovative, technology-driven solutions. Auryis tackles the complex and ever-evolving regulatory landscape faced by pharmaceutical and life science companies, promising to streamline compliance processes and reduce associated risks.

In the rapidly changing world of pharmaceutical and life science regulations, maintaining compliance is a constant challenge. Companies grapple with a myriad of evolving global standards, such as GxP, FDA, and EMA regulations, alongside internal policies and procedures. Manual review processes are often time-consuming, expensive, and prone to human error, leading to potential non-compliance, costly delays in approvals, and even compromised patient safety. Auryis directly addresses these challenges by leveraging the power of artificial intelligence to automate and enhance the entire compliance assessment workflow.

Auryis offers a unique approach to compliance management, seamlessly integrating various functionalities into a single, unified platform. Its ability to ingest and analyze diverse content formats – including standard operating procedures (SOPs), clinical trial documents, training materials, and marketing assets – in real-time sets it apart. The platform intelligently maps this content to relevant external regulations and internal standards, flagging potential non-compliance issues instantly. This proactive approach allows organizations to identify and mitigate risks before they escalate into significant problems.

One of Auryis’ key strengths lies in its “human-in-the-loop” intelligence. While AI drives the automated detection of non-compliance, the system also incorporates human review and feedback. Subject matter experts (SMEs) can validate the AI’s findings, ensuring accuracy and continuously refining the system's precision. This iterative process allows Auryis to learn and adapt, becoming increasingly effective over time. The platform also boasts custom rule integration capabilities, enabling quick adaptation to new policies, study conditions, and temporary guidance.

The continuous learning aspect of Auryis is crucial in an environment where regulations are constantly evolving. By continuously updating its knowledge base, the platform keeps pace with global changes, significantly reducing the manual workload associated with compliance reviews and shortening cycle times. This allows compliance teams to focus on strategic initiatives rather than being bogged down in tedious manual checks. The platform's ability to generate audit-ready insights further streamlines the audit process, minimizing disruption and ensuring preparedness.

Sheshadri Srinivas, CEO of Canarys, emphasized the significance of this launch: "In today's complex regulatory environment, Pharma and Life Sciences organizations face mounting pressure. Auryis directly addresses these challenges, transforming compliance into a faster, smarter, and continuous process. Powered by AI and reinforced by expert validation, it delivers audit-ready insights, lowers non-compliance risk, and drives operational excellence. This is a defining milestone in Canarys' journey, solidifying our position as a product-led company dedicated to delivering durable value."

The business impact of Auryis is projected to be substantial. By automating many aspects of compliance review, the platform significantly reduces both costs and cycle times. It also fosters a culture of proactive risk identification and mitigation, enabling organizations to prevent potential issues before they arise. Ultimately, Auryis aims to facilitate a sustainable shift toward continuous compliance improvement, enhancing operational efficiency and ensuring ongoing adherence to regulatory standards. The platform’s ability to offer guided, standardized reviews also significantly lowers the training burden on compliance teams.

Canarys, with its extensive experience in IT solutions and a team of over 350 technology professionals, is well-positioned to support the adoption and ongoing success of Auryis. The company’s commitment to digital transformation across various industry sectors provides a strong foundation for the platform's development and future expansion. Auryis represents a significant leap forward in AI-powered compliance solutions, promising to reshape the landscape of regulatory compliance within the pharmaceutical and life sciences industries, improving efficiency and ultimately ensuring patient safety.